Unbalanced and self-sustaining intestinal immune response is the signature of IBD, and several cytokines were associated with this condition; among these, tumor necrosis factor (TNF) was the first to be targeted by biological therapies based on monoclonal antibody infusion. This evidence concerns the gene TNF and inflammatory bowel disease.